Investors & Media

Investors & Media

Welcome to our investor page

We aspire to individualize cancer medicine

BioNTech was founded in 2008 on the understanding that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized. To translate this idea into reality, we have combined ground-breaking research with cutting-edge technologies to develop pioneering therapeutics for cancer and beyond. As we prove the value of our approach in the clinic, we will continue to build the partnerships, manufacturing and team required to bring individualized treatments to patients worldwide. From our roots in Mainz, Germany, we are driven to become the leading global biotechnology company for individualized cancer medicine.

 

Press Releases

30 September 2020

BioNTech and Pfizer Announce Nature Publication of German Phase 1/2 Study Data ..

17 September 2020

BioNTech to Acquire GMP Manufacturing Site to Expand COVID-19 Vaccine Productio..

15 September 2020

BioNTech to Receive up to €375M in Funding from German Federal Ministry of Educ..

Press releases (more)

Upcoming Events

October 5 - October 6, 2020

Guggenheim Therapeutics 1st Annual Vaccines and Infectious Disease Conf..

November 10, 2020

Third Quarter 2020 update

Upcoming events (more)

Stock Quote

Sep 30, 2020 /

Data Provided by Refinitiv. Minimum 15 minutes delayed.